232 related articles for article (PubMed ID: 22558238)
1. Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
Iaffaldano P; Viterbo RG; Paolicelli D; Lucchese G; Portaccio E; Goretti B; Direnzo V; D'Onghia M; Zoccolella S; Amato MP; Trojano M
PLoS One; 2012; 7(4):e35843. PubMed ID: 22558238
[TBL] [Abstract][Full Text] [Related]
2. The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis.
Iaffaldano P; Ruggieri M; Viterbo RG; Mastrapasqua M; Trojano M
Brain Behav Immun; 2014 Jan; 35():176-81. PubMed ID: 23994630
[TBL] [Abstract][Full Text] [Related]
3. Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.
Planche V; Moisset X; Morello R; Dumont E; Gibelin M; Charré-Morin J; Saubusse A; Mondou A; Reuter F; Defer G; Pelletier J; Brochet B; Clavelou P
J Neurol Sci; 2017 Nov; 382():148-154. PubMed ID: 29111011
[TBL] [Abstract][Full Text] [Related]
4. Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study.
Sundgren M; Piehl F; Wahlin Å; Brismar T
Mult Scler Relat Disord; 2016 Nov; 10():36-43. PubMed ID: 27919496
[TBL] [Abstract][Full Text] [Related]
5. Multiple sclerosis associated fatigue during natalizumab treatment.
Putzki N; Yaldizli O; Tettenborn B; Diener HC
J Neurol Sci; 2009 Oct; 285(1-2):109-13. PubMed ID: 19560168
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis--a prospective, non-randomized pilot study.
Portaccio E; Stromillo ML; Goretti B; Hakiki B; Giorgio A; Rossi F; De Leucio A; De Stefano N; Amato MP
Eur J Neurol; 2013 Jun; 20(6):986-90. PubMed ID: 23057658
[TBL] [Abstract][Full Text] [Related]
7. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.
Butzkueven H; Kappos L; Pellegrini F; Trojano M; Wiendl H; Patel RN; Zhang A; Hotermans C; Belachew S;
J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1190-7. PubMed ID: 24532785
[TBL] [Abstract][Full Text] [Related]
9. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients.
Kerbrat A; Le Page E; Leray E; Anani T; Coustans M; Desormeaux C; Guiziou C; Kassiotis P; Lallement F; Laplaud D; Diraison P; Rouhart F; Sartori E; Wardi R; Wiertlewski S; Edan G
J Neurol Sci; 2011 Sep; 308(1-2):98-102. PubMed ID: 21665227
[TBL] [Abstract][Full Text] [Related]
10. End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines?
Cathérine D; Annelien P; Anne S; Luc A; Liesbeth VH; Gerlo S; Guy L
Mult Scler Relat Disord; 2020 Jun; 41():102020. PubMed ID: 32146430
[TBL] [Abstract][Full Text] [Related]
11. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
[TBL] [Abstract][Full Text] [Related]
12. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
[TBL] [Abstract][Full Text] [Related]
13. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
Clerico M; Schiavetti I; De Mercanti SF; Piazza F; Gned D; Brescia Morra V; Lanzillo R; Ghezzi A; Bianchi A; Salemi G; Realmuto S; Sola P; Vitetta F; Cavalla P; Paolicelli D; Trojano M; Sormani MP; Durelli L
JAMA Neurol; 2014 Aug; 71(8):954-60. PubMed ID: 24977406
[TBL] [Abstract][Full Text] [Related]
14. Cognitive functioning following one-year natalizumab treatment: A non-randomized clinical trial.
Rorsman I; Petersen C; Nilsson PC
Acta Neurol Scand; 2018 Jan; 137(1):117-124. PubMed ID: 28901547
[TBL] [Abstract][Full Text] [Related]
15. Trajectory of fatigue severity in natalizumab treated multiple sclerosis patients.
Yildiz M; Tettenborn B; Borgwardt S
Clin Neurol Neurosurg; 2013 Jul; 115(7):902-3. PubMed ID: 23021201
[TBL] [Abstract][Full Text] [Related]
16. Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis.
Calabrese M; Rinaldi F; Grossi P; Mattisi I; Bernardi V; Favaretto A; Perini P; Gallo P
Mult Scler; 2010 Oct; 16(10):1220-8. PubMed ID: 20670981
[TBL] [Abstract][Full Text] [Related]
17. The Rao's Brief Repeatable Battery in the study of cognition in different multiple sclerosis phenotypes: application of normative data in a Serbian population.
Dackovic J; Pekmezovic T; Mesaros S; Dujmovic I; Stojsavljevic N; Martinovic V; Drulovic J
Neurol Sci; 2016 Sep; 37(9):1475-81. PubMed ID: 27207679
[TBL] [Abstract][Full Text] [Related]
18. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis.
Fernández-Megía MJ; Casanova B; Magraner MJ; Font-Noguera I; Poveda-Andrés JL
Farm Hosp; 2011; 35(2):75-9. PubMed ID: 20685144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]